DB
SUPN icon

Danske Bank’s Supernus Pharmaceuticals SUPN Stock Holding History

Danske Bank’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$4.97K – 1538
2025
Q4 		$4.97K Hold
100
– – ﹤0.01% 1363
2025
Q3 		$4.78K Hold
100
– – ﹤0.01% 1321
2025
Q2 		$3.15K Hold
100
– – ﹤0.01% 1382
2025
Q1 		$3.27K Hold
100
– – ﹤0.01% 1219
2024
Q4 		$3.62K Sell
100
-400
-80% -$14.1K ﹤0.01% 1232
2024
Q3 		$15.6K Sell
500
-22,083
-98% -$689K ﹤0.01% 1386
2024
Q2 		$604K Buy
+22,583
New +$655K ﹤0.01% 844

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Danske Bank's SUPN Position: Q1 2026 in Review

Danske Bank sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 100 shares — an estimated $4.97K sold.

Danske Bank first reported a position in SUPN in Q2 2024 and held it in 7 quarters. The position peaked at $604K in Q2 2024. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Danske Bank reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Danske Bank sold 100 Supernus Pharmaceuticals shares in Q1 2026, an estimated $4.97K.
  • Danske Bank first reported a position in Supernus Pharmaceuticals in Q2 2024 and held it in 7 quarters.
  • Danske Bank's Supernus Pharmaceuticals position peaked at $604K in Q2 2024.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.